Cited by 68Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesHIV, Drug Use, Sexual Risk

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The Effects of Naloxone Access Laws on Opioid Abuse, Mortality, and Crime

Doleac, Jennifer L., Mukherjee, Anita·2022·The Journal of Law and Economics

Abstract

The United States is experiencing an epidemic of opioid abuse. In response, states have implemented policies including increased access to naloxone, a drug that can save lives when administered during an overdose. There is a concern that widespread naloxone access may unintentionally lead to increased or riskier opioid use by reducing the risk of death from overdose, however. In this paper, we use the staggered timing of state-level naloxone access laws as a natural experiment to measure the effects of broadening access to this lifesaving drug. We find that broadened access led to more opioid-related emergency room visits and more opioid-related theft, with no net measurable reduction in opioid-related mortality. We conclude that naloxone has a clear and important role in harm reduction, yet its ability to combat the opioid epidemic’s death toll may be limited without complementary efforts.

Overview

Integrity signals

Registry

Crossref · 10.1086/719588

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Analyses of interventions intended to reduce overdose mortality or consequences of criminalization have similarly relied on models that did not account for the spread of fentanyl across the US.

    “Analyses of interventions intended to reduce overdose mortality or the consequences of criminalization, ranging from increased naloxone distribution38 to relaxed state marijuana laws,39 have similarly relied on models that did not account for the spread of fentanyl across the US.”

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 37

  1. 10.1001/jamainternmed.2019.0272 · DOI
  2. 10.1257/pol.20170082 · DOI
  3. 10.1111/ecoj.12451 · DOI
  4. 10.1086/261558 · DOI
  5. Black Bernard, Simulated Power Analyses for Observational Studies: An Application to the Affordable Care Act Medicaid Expansion. Working Paper No. 25568
  6. 10.1016/j.jue.2018.01.007 · DOI
  7. Borusyak Kirill, Revisiting Event Study Designs. Working paper
  8. 10.1257/pol.20160094 · DOI
  9. 10.1093/restud/rdv053 · DOI
  10. 10.1086/422978 · DOI
  11. 10.1162/003465303772815754 · DOI
  12. 10.1016/j.jhealeco.2012.11.003 · DOI
  13. 10.1016/j.drugalcdep.2015.10.013 · DOI
  14. 10.1515/bejeap-2020-0253 · DOI
  15. 10.52324/001c.7932 · DOI
  16. 10.1162/rest_a_00755 · DOI
  17. 10.1016/S0167-6296(97)00046-5 · DOI
  18. Hansen Benjamin, The Taxation of Recreational Marijuana: Evidence from Washington State. Working Paper No. 23632
  19. Kilby Angela, Opioids for the Masses: Welfare Tradeoffs in the Regulation of Narcotic Pain Medications. Working paper
  20. 10.2105/AJPH.2012.300989 · DOI
  21. 10.1162/qjec.121.3.1063 · DOI
  22. MacCoun Robert, Research on Drugs-Crime Linkages: The Next Generation. Pp. 65–95 in Toward a Drugs and Crime Research Agenda for the 21st Century
  23. Maclean Johanna Catherine, Economic Studies on the Opioid Crisis: A Review. Working Paper No. 28067
  24. Mallatt Justine, The Effect of Prescription Drug Monitoring Programs on Opioid Prescriptions and Heroin Crime Rates. Working paper
  25. 10.1016/j.addbeh.2018.03.014 · DOI
  26. 10.1056/NEJMsa1514387 · DOI
  27. 10.3368/jhr.51.2.0414-6298R1 · DOI · Paper page
  28. Moore Timothy J, 2021, Schnepel
  29. 10.1080/08897077.2015.1010032 · DOI
  30. Packham Analisa, Are Syringe Exchange Programs Helpful or Harmful? New Evidence in the Wake of the Opioid Epidemic. Working Paper No. 26111
  31. 10.1086/260352 · DOI
  32. Quinones Sam, 2015, Dreamland: The True Tale of America’s Opiate Epidemic.
  33. 10.1086/700703 · DOI
  34. 10.1111/add.14144 · DOI
  35. Schnell Molly, Physician Behavior in the Presence of a Secondary Market: The Case of Prescription Opioids. Working paper
  36. 10.1002/pam.21972 · DOI
  37. 10.1016/j.jpubeco.2014.12.008 · DOI

Cited by

Sorted by citations

Metadata

Authors
Doleac, J. L., & Mukherjee, A.
Affiliations
  • Texas A&M University (US)
  • University of Wisconsin–Madison (US)
Venue
The Journal of Law and Economics
Published
2022-05-01
Volume
65
Issue
2
Pages
211-238
ISSN
  • 0022-2186 (ISSN-L)
  • 1537-5285
OpenAlex
W4294974554
Cited by
68
References
2
Citations by year
2026: 7 · 2025: 12 · 2024: 21 · 2023: 23 · 2022: 5
FWCI
13.46
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Law and Economics (publishedVersion)
  • bepress Legal Repository (submittedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
Keywords
naloxone, opioid epidemic, opioid abuse, opioid-related deaths, harm reduction, drug policy, overdose prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review